Published in Am J Pathol on March 01, 2002
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal (2007) 2.03
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 1.44
Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol (2006) 1.44
Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer (2006) 1.35
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) (2013) 1.31
Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. Am J Pathol (2003) 1.24
Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut (2005) 1.22
Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer (2010) 1.18
FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer (2006) 1.16
Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia (2006) 1.06
Melanoma biomarkers: current status and vision for the future. Nat Clin Pract Oncol (2008) 1.05
EphA2 is a critical oncogene in melanoma. Oncogene (2011) 1.05
The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences. J Biol Chem (2006) 1.03
Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer (2008) 1.03
Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer (2008) 1.02
EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther (2009) 1.00
Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer (2005) 0.98
Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch (2005) 0.97
Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol (2010) 0.95
Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr (2012) 0.93
Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol (2010) 0.90
Identify lymphatic metastasis-associated genes in mouse hepatocarcinoma cell lines using gene chip. World J Gastroenterol (2005) 0.89
Reactive oxygen species driven angiogenesis by inorganic nanorods. Nano Lett (2011) 0.88
Long-lasting molecular changes in human skin after repetitive in situ UV irradiation. J Invest Dermatol (2008) 0.87
Correlative studies on bFGF mRNA and MMP-9 mRNA expressions with microvascular density, progression, and prognosis of gastric carcinomas. World J Gastroenterol (2005) 0.82
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther (2014) 0.80
Predictive biomarkers for dasatinib treatment in melanoma. Oncoscience (2014) 0.79
BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer (2016) 0.77
Aberrant expression of hSef and Sprouty4 in endometrial adenocarcinoma. Oncol Lett (2015) 0.76
Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas. Int J Clin Exp Pathol (2015) 0.75
Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. Healthcare (Basel) (2014) 0.75
Novel anti-EPHA2 antibody, DS-8895a for cancer treatment. Cancer Biol Ther (2016) 0.75
Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women. Oncol Lett (2017) 0.75
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 25.41
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (1992) 7.92
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med (2001) 5.52
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun (1992) 5.31
Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci (1995) 4.97
Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) (1999) 4.85
Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 4.26
The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem (1996) 3.53
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A (2000) 3.16
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol (1993) 2.44
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A (2001) 2.36
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res (1996) 2.36
Molecular determinants of ovarian cancer plasticity. Am J Pathol (2001) 2.32
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol (2001) 2.20
Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol (1997) 2.15
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res (1998) 2.06
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J (1989) 1.84
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res (2001) 1.73
Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med (1997) 1.72
Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology (1999) 1.70
Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res (2000) 1.65
Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops. J Pathol (1998) 1.62
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res (2000) 1.55
Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol (2001) 1.49
The Eph family of receptors. Curr Opin Cell Biol (1997) 1.45
Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J Pathol (2001) 1.42
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (1997) 1.40
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer (1997) 1.40
Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun (1993) 1.38
bFGF as an autocrine growth factor for human melanomas. Oncogene Res (1988) 1.35
Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest (1992) 1.34
Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer (1997) 1.32
Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer (1999) 1.28
Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. Am J Pathol (1994) 1.27
The Eph family in the patterning of neural development. Curr Biol (1997) 1.26
Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res (2000) 1.26
A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol (1990) 1.25
Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res (1995) 1.25
Expression and function of angiopoietin-1 in breast cancer. Br J Cancer (2000) 1.24
Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol (1997) 1.23
Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer (2001) 1.21
p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer (1998) 1.19
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol (1998) 1.19
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res (1997) 1.17
Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol (1999) 1.17
Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene (1999) 1.14
Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest (1999) 1.11
Tyrosine phosphorylation of L1 family adhesion molecules: implication of the Eph kinase Cek5. J Neurosci Res (1997) 1.09
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer (2000) 1.09
Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol (1995) 1.08
Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res (1999) 1.06
Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol (1999) 1.05
Angiogenesis and cancer metastasis. Cancer J (2000) 1.03
Cell signalling. Receptor orphans find a family. Curr Biol (1995) 1.02
Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res (2001) 1.02
IL-8 expression in malignant melanoma: implications in growth and metastasis. Histol Histopathol (2000) 1.01
Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res (2001) 1.00
Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol (1999) 1.00
Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun (1995) 0.98
bFGF and tumor angiogenesis--back in the limelight? Nat Med (1997) 0.98
Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol (2001) 0.96
The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Hum Pathol (1999) 0.95
Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat. Br J Cancer (1999) 0.91
Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res (1999) 0.91
Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol (2001) 0.90
The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma. J Cutan Pathol (1996) 0.80
Basic fibroblast growth factor is a morphogenic modulator in kidney vessel development. Kidney Int (1998) 0.79
Angiogenesis during tumor progression in human malignant melanoma. EXS (1992) 0.79
Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma. Melanoma Res (1997) 0.78
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res (2003) 1.89
Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol (2002) 1.11
Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One (2009) 1.09
ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol (2007) 1.05
Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Clin Cancer Res (2007) 0.99
Gene expression profiles in prostate cancer: association with patient subgroups and tumour differentiation. Int J Oncol (2005) 0.98
Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Anal Biochem (2007) 0.86
Tumor necrosis is a prognostic factor in thick cutaneous melanoma. Am J Surg Pathol (2012) 0.86
Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. Urology (2003) 0.81
Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. J Urol (2005) 0.77
Frequencies of KIT and GNAQ mutations in acral melanoma. J Cutan Pathol (2014) 0.75
Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncol Rep (2005) 0.75